-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

731.O1.6 731. Clinical Autologous Transplantation: Results I

Clinical Autologous Transplantation: Results Program: Oral and Poster Abstracts
Type: Oral
Sunday, December 6, 2015: 4:30 PM-6:00 PM
W224CDGH, Level 2 (Orange County Convention Center)
Moderators:
Gordon Cook, MD, PhD, University of Leeds and Laurent Garderet, MD PhD, Hospital Saint Antoine

Disclosures:
Cook: Janssen: Consultancy , Research Funding , Speakers Bureau ; Amgen: Consultancy , Speakers Bureau ; Celgene: Consultancy , Research Funding , Speakers Bureau ; BMS: Consultancy ; Sanofi: Consultancy , Speakers Bureau ; Takeda Oncology: Consultancy , Research Funding , Speakers Bureau . Garderet: BMS: Consultancy , Honoraria ; Amgen: Consultancy .
4:30 PM
391
Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial)

Michel Attal1, Valerie Lauwers-Cances, MD2*, Cyrille Hulin, MD3*, Thierry Facon4, Denis Caillot5*, Martine Escoffre6*, Bertrand Arnulf7*, Margaret MACRO, MD8,9*, Karim Belhadj, MD10*, Laurent Garderet, MD11, Murielle Roussel, MD12*, Claire Mathiot, MD13*, Herve Avet-Loiseau14*, Nikhil C. Munshi, MD15, Paul G. Richardson, MD16, Kenneth C. Anderson, M.D17, jean Luc Harousseau18* and Philippe Moreau19*

1Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France
2CHU Toulouse, Toulouse, France
3CHRU Hopitaux de Brabois, NANCY CEDEX, France
4Maladies du Sang, Hôpital Claude Huriez, CHRU Lille, Lille, France
5Hôpital du Bocage, Dijon, France
6CHU Rennes, Rennes, France
7Saint Louis Hosp., Paris, France
8CHU Caen, Caen, France
9CHU Caen, CAEN, France
10CHU Henri Mondor, Creteil, France
11Hopital St Antoine, Paris, France
12Institut Universitaire du Cancer and University Hospital, Hematology department, Toulouse, France
13IFM, Paris, France
14IUCT-Oncopole, Toulouse, France
15LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
16Division of Hematologic Malignancy, Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
17Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
18HAS, paris, France
19Department of Hematology, Nantes University Hospital, Nantes, France
4:45 PM
392
Autologous Transplantation Versus Cyclophosphamide-Lenalidomide-Prednisone Followed By Lenalidomide-Prednisone Versus Lenalidomide Maintenance in Multiple Myeloma: Long-Term Results of a Phase III TrialClinically Relevant Abstract

Francesca Gay1*, Valeria Magarotto, MD1*, Maria Teresa Petrucci2, Francesco Di Raimondo2, Luděk Pour3*, Tommaso Caravita2*, Vlastimil Scudla4*, Anna Maria Cafro2*, Anna Marina Liberati2, Stefano Spada1*, Maisnar Vladimir5*, Norbert Pescosta2*, Roberto Ria2*, Massimo Offidani2, Sara Bringhen1*, Annalisa Bernardini1*, Francesca Patriarca2*, Paolo Corradini2, Roberto Foà2*, Nicola Cascavilla2*, Lucio Catalano2*, Andrew Spencer6, Roman Hajek7, Mario Boccadoro, MD1 and Antonio Palumbo1

1Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy
2Italian Multiple Myeloma Network, GIMEMA, Italy
3University Hospital Brno and Faculty of Medicine MU, Brno, Czech Republic
4Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic
5Department of Clinical Hematology, University Hospital, Hradec Kralove, Czech Republic
6Alfred Health-Monash University, Melbourne, Australia
7Dept. of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
5:00 PM
393
Bortezomib, Thalidomide and Dexamethasone (VTD) Is Superior to Bortezomib, Cyclophosphamide and Dexamethasone (VCD) Prior to Autologous Stem Cell Transplantation for Patients with De Novo Multiple Myeloma. Results of the Prospective IFM 2013-04 TrialClinically Relevant Abstract

Philippe Moreau1*, Cyrille Hulin2*, Margaret MACRO, MD3*, Denis Caillot4*, Carine Chaleteix5*, Murielle Roussel6*, Laurent Garderet, MD7, Bruno Royer, MD8*, Sabine Brechignac, MD9*, Mourad Tiab, MD10*, Mathieu Puyade, md11*, Martine Escoffre12*, Anne-Marie Stoppa, MD13, Thierry Facon14, Brigitte Pégourie15*, Driss Chaoui, MD16*, Arnaud Jaccard, MD, PhD17*, Borhane Slama18*, Gerald Marit19*, Kamel Laribi20*, Pascal Godmer, MD21*, Odile Luycx22*, Jean Claude Eisenmann, MD23*, Olivier Allangha24*, Sylvie Glaisner25*, Mamoun Dib26*, Carla Araujo27*, Jean Fontan28*, Karim Belhadj, MD29*, Marc Wetterwald, MD, PhD30*, Veronique Dorvaux31*, Jean-Paul Fermand32, Philippe Rodon, MD33, Brigitte Kolb34*, Pascal Lenain, MD35*, Lucie Planche36*, Laetitia Biron36*, Helene Caillon37*, Herve Avet-Loiseau38*, Thomas Dejoie37* and Michel Attal39

1University of Nantes, Nantes, France
2Service Hematologie, CHRU Hopitaux de Brabois, Vandoeuvre cedex, France
3Hopital Cote De Nacre, Caen Cedex 9, France
4Hôpital du Bocage, Dijon, France
5university hospital, Clermont Ferrand, France
6Hopital Purpan, Toulouse, France
7Hôpital Saint Antoine, Paris, France
8Hematology, Centre Hospitalier Universitaire, Amiens, France
9Hopital Avicenne, bobigny, France
10Hopital la Roche Sur Yon, La Roche Sur Yon Cedex 9, France
11university hospital, poitiers, France
12CHU Rennes, Rennes, France
13Institut Paoli Calmettes, Marseille, France
14Maladies du Sang, Hôpital Claude Huriez, CHRU Lille, Lille, France
15CHU de Grenoble - Hôpital Albert Michallon, Grenoble, France
16Hematology, CH Victor Dupouy, Argenteuil, France
17Department of Hematology, Centre National de Référence Maladies Rares: Amylose AL et Autres Maladies à Dépôts, CHU Limoges, Limoges, France
18university hospital, avignon, France
19CHU, Bordeaux, France
20Centre Hospitalier, Le Mans, France
21CH de Vannes, Vannes, France
22university hospital, lorient, France
23Hematology Department, CH Mulhouse, Mulhouse, France
24university hospital, saint-brieuc, France
25institut curie, paris, France
26Hématologie - CHU - Hôpital du Bocage, Angers, France
27Centre Hospitalier de la côte basque, Bayonne, France
28Service Hematologie, CHU Besancon, Besancon, France
29CHU Henri Mondor, Creteil, France
30CHD Dunkerque, Dunkerque, France
31Medecine Interne, Hopital Notre Dame de Bon Secours, Metz-Thionville, France
32Service d'Immuno-Hematologie, Hopital Saint-Louis, APHP, Paris, France
33Hematology, Centre Hospitalier, Perigueux, France
34Hopital Robert Debre, Reims Cedex, France
35Hematology department, Centre Henri Becquerel, Rouen, France
36university hospital, nantes, France
37Biochemistry Laboratory, Nantes University Hospital, Nantes, France, Nantes, France
38IUCT-Oncopole, Toulouse, France
39Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France
5:15 PM
394
A Salvage Autologous Stem Cell Transplant (ASCT2) Induces Superior Overall Survival Following Bortezomib-Containing Re-Induction Therapy for Relapsed Multiple Myeloma (MM): Results from the Myeloma X (Intensive) Trial

Gordon Cook, MD, PhD1, Cathy Williams2*, David A Cairns3*, Anna Hockaday4*, Jamie Cavenagh5, John A Snowden, MD, FRCP, FRCPath6, Christopher Parrish, MD7*, Kwee L Yong, MBChB, PhD8*, Jim Cavet, FRCPath9*, Hannah Hunter10, Jennifer Bird11*, Guy Pratt, MD12, Sally Chown13*, Earnest Heartin14*, Sheila J.M. O'Connor15*, John Ashcroft, MD, MBBChir, PhD, MRCP, MA, FRCPath16, Julia Brown, PhD17* and Curly Morris, MD18

1University of Leeds, Leeds, United Kingdom
2Centre for Clinical Haematology, Nottingham University Hospitals, Nottingham, United Kingdom
3Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom
4Clinical Trials Research Unit, Univeristy of Leeds, Leeds, United Kingdom
5Dept. of Hematology, St. Bartholomew's Hospital, London, United Kingdom
6Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom
7St James's Institute of Oncology, Leeds, United Kingdom
8Department of Haematology, UCL Cancer Institute, London, United Kingdom
9The Christie NHS Foundation Trust, Manchester, United Kingdom
10Department of Haematology, Derriford Hospital, Plymouth, United Kingdom
11University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom
12Centre for Clinical Haematology, Birmingham Heartlands Hospital, Birmingham, United Kingdom
13Gloucestershire Hospitals Trust, Deaprtment of Haematology, Gloucester, United Kingdom
14Conwy & Denbighshire NHS Trust, Department of Haematology, Bodelwyddan, United Kingdom
15HMDS, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
16Dept. of Haematology, Pinderfields Hospital, Wakefield, United Kingdom
17Univeristy of Leeds, Clincial Trials Research Unit, Leeds, United Kingdom
18Centre for Cancer Research & Cell Biology, Queen's University of Belfast, Belfast, United Kingdom
5:30 PM
395
Prospective Evaluation of MRI and PET-CT at Diagnosis and before Maintenance Therapy in Symptomatic Patients with Multiple Myeloma Included in the IFM/DFCI 2009 TrialClinically Relevant Abstract

Philippe Moreau, MD, PhD1*, Michel Attal2, Lionel Karlin3*, Laurent Garderet4, Thierry Facon5, Margaret Macro6*, Lotfi Benboubker7*, Denis Caillot8*, Martine Escoffre9*, Anne-Marie Stoppa, MD10, Kamel Laribi11*, Cyrille Hulin12*, Gerald Marit13*, Jean Richard Eveillard14*, Florence Caillon15*, Caroline Bodet15*, Brigitte Pégourie16*, Veronique Dorvaux17*, Carine Chaleteix18*, Paul G. Richardson, MD19, Kenneth C. Anderson, MD19, Hervé Avet-Loiseau, MD20*, Aurelie Gaultier15*, jean-Michel Nguyen15*, Benoit Dupas15* and Francoise Bodere15*

1Nantes University Hospital, Hôtel Dieu, Nantes, France
2Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France
3Service d'Hématologie, Centre Hospitalier Lyon Sud, Pierre Bénite, France
4Hematology, CHU St Antoine, Paris, France
5Maladies du Sang, Hôpital Claude Huriez, CHRU Lille, Lille, France
6Hopital Cote De Nacre, Caen Cedex 9, France
7CHU, Tours, France
8Hôpital du Bocage, Dijon, France
9CHU Rennes, Rennes, France
10Institut Paoli Calmettes, Marseille, France
11Centre Hospitalier, Le Mans, France
12Service Hematologie, CHRU Hopitaux de Brabois, Vandoeuvre cedex, France
13CHU, Bordeaux, France
14university hospital, Brest, France
15university hospital, nantes, France
16CHU de Grenoble - Hôpital Albert Michallon, Grenoble, France
17Medecine Interne, Hopital Notre Dame de Bon Secours, Metz-Thionville, France
18university hospital, Clermont Ferrand, France
19Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
20Centre de Recherche en Cancérologie de Toulouse Institut National de la Santé, Toulouse, France
5:45 PM
396
Post-Transplant Therapy Is More Important Than Induction Regimen Choice in Autologous Hematopoietic Cell Transplantation (AHCT) Recipients for Multiple Myeloma (MM)

Robert Frank Cornell, MD1, Luciano J Costa, MD, PhD2, Adetola A. Kassim, MD, MS3, Racquel Inns-Shelton, MD4*, Amrita Krishnan5, Tomer Mark, MD6*, Yago Nieto, MD, PhD7, Cristina J Gasparetto8, Anita D'Souza, MBBS, MD9,10, Parameswaran Hari, MD, MRCP, MS11, Mei-Jie Zhang, PhD12,13* and Jiaxing Huang, MS12*

1Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
2Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL
3Department of Medicine, Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN
4University of Alabama at Birmingham, Birmingham, AL
5City of Hope National Medical Center, Duarte, CA
6Department of Medicine, Weill Cornell Medical College, New York, NY
7M.D. Anderson Cancer Center, Houston, TX
8Duke University Medical Center, Durham, NC
9Froedtert Memorial Lutheran Hospital, Milwaukee, WI
10CIBMTR (Center for International Transplant Research), Medical College of Wisconsin, Milwaukee, WI
11Medical College of Wisconsin, Milwaukee, WI
12CIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI
13Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI
See more of: Clinical Autologous Transplantation: Results
See more of: Oral and Poster Abstracts
<< Previous Session | Next Session >>

*signifies non-member of ASH